Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2003
03/06/2003WO2002102382A9 A PROCESS FOR PREPARING PAROXETINE HCl WHICH LIMITS FORMATION OF PINK COLORED COMPOUNDS
03/06/2003WO2002102381A9 Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage
03/06/2003WO2002094218A3 Delivery of alprazolam, estazolam, midazolam or triazolam through an inhalation route
03/06/2003WO2002092122A3 Use of osteopontin for the treatment and/or prevention of neurologic diseases
03/06/2003WO2002089794A8 Method for treating neuropathic pain and pharmaceutical preparation therefor
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002085945A3 Vhh single heavy chain antibody and a method for its preparation in a mammal
03/06/2003WO2002074249A3 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
03/06/2003WO2002074243A9 Methods and compositions for the treatment and/or diagnosis of neurological diseases and disorders
03/06/2003WO2002074200B1 Formulations containing propofol and a sulfoalkyl ether cyclodextrin
03/06/2003WO2002072570A3 Non-imidazole compounds as histamine h3 antagonists
03/06/2003WO2002069951A3 Composition containing a nefazonoid such as nefazodone and a serotonin-inhibitor such as fluoxetine
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002064731A3 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines
03/06/2003WO2002060929A3 Polymer conjugates of neublastin and methods of using same
03/06/2003WO2002059302A3 Regulation of human serotonin-like g protein-coupled receptor
03/06/2003WO2002047671A3 Lactam compound to inhibit beta-amyloid peptide release or synthesis
03/06/2003WO2002043507A3 Nutrient supplements and methods for treating autism and for preventing the onset of autism
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002031151A3 Lipocalins
03/06/2003WO2002028481A3 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
03/06/2003WO2002026947A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
03/06/2003WO2002024672A3 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
03/06/2003WO2002022801A3 Mammalian receptor genes and uses
03/06/2003WO2002020516A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
03/06/2003WO2002016430A3 Peptide with effects on cerebral health
03/06/2003WO2002007675A3 Omega-conopeptides
03/06/2003WO2002005797A8 Use of dopamine d2/d3 receptor agonists to treat fibromyalgia
03/06/2003WO2001098361A9 Agonist anti-trk-c monoclonal antibodies
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001066596A9 Human fgf-23 gene and gene expression products
03/06/2003US20030045728 Indol-3-yl derivatives
03/06/2003US20030045720 Mixing the narcotic alkaloid with an acid in the presence of a catalyst in the substantial absence of hydrogen gas
03/06/2003US20030045583 Novel succinate salt of O-desmethyl-venlafaxine
03/06/2003US20030045580 Making, by coating ibuprofen or its salt with hydroxypropylmethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropylcellulose or gelatin as binder, in specified weight percents; dosage forms
03/06/2003US20030045578 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
03/06/2003US20030045576 Composition for pain mediation and apparatus and method of use thereof
03/06/2003US20030045574 Such as alpha-phenyl-N-(7-tert-butoxycarbonylamino-3,5-dimethyladamantane)nitrone for treatment of neurological/ inflammatory diorders, and aging, which result from the overproduction of nitric oxide
03/06/2003US20030045569 Difluoromethylene aromatic ethers as inhibitors of glycine transport
03/06/2003US20030045567 (-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045564 Saururus chinensis extract for prevention and treatment of neurodegenerative disease
03/06/2003US20030045563 Comprises cyclooxygenase-2 inhibitors (celecoxib, rofecoxib); water solubility; vasodilation/headache relief; for inhibition of precipitation and/or crystallization in gastrointestinal fluids
03/06/2003US20030045558 Such as 2-(4-(2-(2-(4-(3,5-dimethyl-isoxazol-4-yl)-phenyl)-5-methyloxazol-4-yl) -ethyoxy)-phenoxy)-2-methylpropionic acid for treatment of diabetes (lowering serum triglycerides)
03/06/2003US20030045557 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
03/06/2003US20030045556 Aryl-N-cyanoguanidines and methods related thereto
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045533 Phosphodiesterase 4 inhibitors
03/06/2003US20030045532 Triazolo-pyrimidine derivatives as ligands for gaba receptors
03/06/2003US20030045530 Administering a piperazine or piperidine coupled through a linker to a benzhydril
03/06/2003US20030045529 Method for specifically potentiating N-type Ca2+ channel activity
03/06/2003US20030045527 Treating central nervous system or gastrointestinal disorders
03/06/2003US20030045526 Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one
03/06/2003US20030045523 Nicotinic cholinergic receptor antagonists
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045519 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion)
03/06/2003US20030045517 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045514 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030045478 Treating diseases such as cardiac and cerebral ischemia or reperfusion injury, sepsis and bacterial meningitis.
03/06/2003US20030045461 Composition and methods of esterified nitroxides gated with carboxylic acids
03/06/2003US20030045460 Orally administered peptides to ameliorate atherosclerosis
03/06/2003US20030045450 Administering a glycine-site antagonist at the NMDA receptor, e.g., felbamate, for spasticity, symptomatic depression or to protect cells from the consequences of obesity
03/06/2003US20030045449 Pharmaceutical combinations for the treatment of neurodegenerative diseases
03/06/2003US20030044898 Nucleotide sequences coding polypeptide for use in the treatment of asthma, parkinson's, heart defects, hypotension, urogenital and bone disorders
03/06/2003US20030044464 Sustained-release, oral pharamaceutical forms of formulation
03/06/2003US20030044458 Oral dosage form comprising a therapeutic agent and an adverse-effect agent
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030041602 Process for production of nanoparticles and microparticles by spray freezing into liquid
03/06/2003CA2468466A1 Use of pregnane-diones or diols as neuropathic analgesic agents
03/06/2003CA2458855A1 Composition for treating parkinson's disease containing a cb1 receptor antagonist and a product activating dopaminergic neurotransmission in the brain
03/06/2003CA2458622A1 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
03/06/2003CA2458574A1 Reagents and methods for smooth muscle therapies
03/06/2003CA2458443A1 Bioadhesive compositions and methods for enhanced mucosal drug absorption
03/06/2003CA2458375A1 Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease
03/06/2003CA2458261A1 Differentiation of neural stem cells and therapeutic use thereof
03/06/2003CA2458217A1 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2458015A1 Analgetic pyrroline derivatives
03/06/2003CA2457885A1 Antimicrobial and anti-inflammatory peptides
03/06/2003CA2457846A1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003CA2457794A1 Novel synthetic ganglioside derivatives and compositions thereof
03/06/2003CA2457532A1 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/06/2003CA2457341A1 A new extended release oral dosage form
03/06/2003CA2457339A1 A new extended release oral dosage form
03/06/2003CA2456480A1 A combination of quetiapine and zolmitriptan
03/06/2003CA2456420A1 Novel cyclohexyl sulphones
03/06/2003CA2455773A1 Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
03/06/2003CA2455497A1 Amidine derivatives for treating amyloidosis
03/06/2003CA2455311A1 Rapamycin dialdehydes
03/06/2003CA2455308A1 Rapamycin 29-enols
03/06/2003CA2451740A1 Composition comprising wenguanguo extracts, methods for preparing same and uses thereof
03/06/2003CA2430267A1 Hydrazinopeptoids and their uses for treating cancers
03/06/2003CA2421499A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the same and pharmaceutical agent containing the same as active ingredient
03/05/2003EP1288226A1 Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288222A1 Peptidic compounds selectively binding to P-selectin
1 ... 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 ... 1833